JP2024105229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105229A5 JP2024105229A5 JP2024053871A JP2024053871A JP2024105229A5 JP 2024105229 A5 JP2024105229 A5 JP 2024105229A5 JP 2024053871 A JP2024053871 A JP 2024053871A JP 2024053871 A JP2024053871 A JP 2024053871A JP 2024105229 A5 JP2024105229 A5 JP 2024105229A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 48
- 102000036639 antigens Human genes 0.000 claims 48
- 108091007433 antigens Proteins 0.000 claims 48
- 239000012634 fragment Substances 0.000 claims 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims 41
- 101710092462 Alpha-hemolysin Proteins 0.000 claims 10
- 101710197219 Alpha-toxin Proteins 0.000 claims 10
- 101710124951 Phospholipase C Proteins 0.000 claims 10
- 101710198480 Clumping factor A Proteins 0.000 claims 8
- 239000002776 alpha toxin Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100523490 Dictyostelium discoideum rab8A gene Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702762P | 2018-07-24 | 2018-07-24 | |
| US62/702,762 | 2018-07-24 | ||
| JP2021503901A JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| PCT/US2019/043254 WO2020023644A2 (en) | 2018-07-24 | 2019-07-24 | Antibody directed against s. aureus clumping factor a (clfa) |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Division JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105229A JP2024105229A (ja) | 2024-08-06 |
| JP2024105229A5 true JP2024105229A5 (enExample) | 2024-10-24 |
Family
ID=67539640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Active JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| JP2024053871A Pending JP2024105229A (ja) | 2018-07-24 | 2024-03-28 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Active JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11155606B2 (enExample) |
| EP (1) | EP3840838A2 (enExample) |
| JP (2) | JP7525471B2 (enExample) |
| KR (1) | KR20210035846A (enExample) |
| CN (2) | CN119176871A (enExample) |
| AU (1) | AU2019309366B2 (enExample) |
| BR (1) | BR112021001214A2 (enExample) |
| CA (1) | CA3107463A1 (enExample) |
| MX (1) | MX2021000889A (enExample) |
| WO (1) | WO2020023644A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2917360T3 (da) * | 2012-11-06 | 2020-03-30 | Medimmune Llc | Antistoffer mod S. aureus-overflade-determinanter |
| DE102018115012A1 (de) | 2018-06-21 | 2019-12-24 | Carl Zeiss Microscopy Gmbh | Teilchenstrahlsystem |
| CA3107463A1 (en) * | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| JP7459075B2 (ja) | 2018-10-09 | 2024-04-01 | メディミューン，エルエルシー | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| TWI743626B (zh) | 2019-01-24 | 2021-10-21 | 德商卡爾蔡司多重掃描電子顯微鏡有限公司 | 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品 |
| DE102019008249B3 (de) | 2019-11-27 | 2020-11-19 | Carl Zeiss Multisem Gmbh | Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt |
| AR132641A1 (es) * | 2023-05-09 | 2025-07-16 | Astrazeneca Ab | Anticuerpos biespecíficos anti-pseudomonas con regiones fc modificadas y métodos de uso de los mismos |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002072600A2 (en) | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| EP1479695B1 (en) | 2003-05-14 | 2010-02-17 | Kenta Biotech AG | Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CN101466406B (zh) | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| CN101802008B (zh) | 2007-08-21 | 2015-04-01 | 安美基公司 | 人类c-fms抗原结合蛋白 |
| CN101951948B (zh) | 2007-08-31 | 2015-12-09 | 芝加哥大学 | 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物 |
| US20110152173A1 (en) | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| EP2391384A4 (en) | 2009-01-29 | 2012-12-26 | Medimmune Llc | HUMAN ANTI-IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-TIME AND USE THEREOF FOR TREATMENTS IN ONCOLOGY AND FOR AUTOIMMUNE AND IGNITION |
| CN102695724B (zh) | 2009-05-18 | 2016-08-24 | 维尔茨堡尤利乌斯·马克西米利安大学 | 指向金黄葡萄球菌表位isaa或isab的抗体或其片段 |
| BR112012029521A2 (pt) | 2010-05-05 | 2018-03-06 | New York University | leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas. |
| MX375113B (es) | 2011-02-08 | 2025-03-04 | Medimmune Llc | Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso. |
| WO2012177658A2 (en) | 2011-06-19 | 2012-12-27 | New York Univeristy | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| JP6186427B2 (ja) | 2012-03-19 | 2017-08-23 | テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー． | 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 |
| CN112316135A (zh) | 2012-11-06 | 2021-02-05 | 米迪缪尼有限公司 | 治疗金黄色葡萄球菌相关疾病的方法 |
| DK2917360T3 (da) | 2012-11-06 | 2020-03-30 | Medimmune Llc | Antistoffer mod S. aureus-overflade-determinanter |
| BR112016008275A2 (pt) | 2013-10-17 | 2017-10-03 | Arsanis Biosciences Gmbh | Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora |
| US9644023B2 (en) | 2013-12-09 | 2017-05-09 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| BR112016014163A2 (pt) | 2013-12-19 | 2018-01-09 | Arsanis Biosciences Gmbh | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado |
| ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| KR20170136637A (ko) | 2015-04-17 | 2017-12-11 | 알사니스 바이오사이언시스 게엠베하 | 항-스타필로코커스 아우레우스 항체 배합 제제 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
| CA3107463A1 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| JP7459075B2 (ja) | 2018-10-09 | 2024-04-01 | メディミューン，エルエルシー | スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体 |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
-
2019
- 2019-07-24 CA CA3107463A patent/CA3107463A1/en active Pending
- 2019-07-24 US US16/521,223 patent/US11155606B2/en active Active
- 2019-07-24 EP EP19749544.3A patent/EP3840838A2/en active Pending
- 2019-07-24 JP JP2021503901A patent/JP7525471B2/ja active Active
- 2019-07-24 WO PCT/US2019/043254 patent/WO2020023644A2/en not_active Ceased
- 2019-07-24 AU AU2019309366A patent/AU2019309366B2/en active Active
- 2019-07-24 KR KR1020217005010A patent/KR20210035846A/ko active Pending
- 2019-07-24 MX MX2021000889A patent/MX2021000889A/es unknown
- 2019-07-24 CN CN202411220211.6A patent/CN119176871A/zh active Pending
- 2019-07-24 BR BR112021001214-1A patent/BR112021001214A2/pt unknown
- 2019-07-24 CN CN201980058857.XA patent/CN112672788B/zh active Active
-
2021
- 2021-09-23 US US17/483,162 patent/US11970527B2/en active Active
-
2024
- 2024-03-28 JP JP2024053871A patent/JP2024105229A/ja active Pending
- 2024-03-29 US US18/621,921 patent/US20240352098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105229A5 (enExample) | ||
| JP2023075294A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| EP2890711B1 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
| JPWO2019175223A5 (enExample) | ||
| CN106749667B (zh) | 一种抗癌胚抗原的纳米抗体及其应用 | |
| TW202126693A (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| TW202200621A (zh) | 與人IL-4Rα中特定表位結合的抗體及其應用 | |
| WO2022037527A1 (zh) | 结合bcma的单可变结构域及抗原结合分子 | |
| TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| CN119306838B (zh) | 一种抗人pd-1的鲨鱼纳米抗体及其应用 | |
| JP2022122865A5 (enExample) | ||
| CN118165106A (zh) | 抗犬il-31单克隆抗体及其应用 | |
| JP2019510474A (ja) | トロンビン抗体、その抗原結合フラグメント及び医薬用途 | |
| JP2019531063A (ja) | インターロイキン−６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント | |
| WO2022037528A1 (zh) | 结合bcma的单可变结构域及抗原结合分子 | |
| Yuan et al. | Construction of human nonimmune library and selection of scFvs against IL-33 | |
| JPWO2020023644A5 (enExample) | ||
| CN115925934B (zh) | 一种稳定性提高的人源化单克隆抗体及其应用 | |
| CN113512119B (zh) | 一种抗ca125的纳米抗体5d2及其应用 | |
| WO2019011167A1 (zh) | 双特异性重组蛋白 | |
| TWI773264B (zh) | 結合人ngf的抗體、其製備方法和用途 | |
| EP2851427A1 (en) | Method for producing and obtaining variable domains of anti-digoxin monoclonal antibody fab fragment using the molecular biology cloning technique | |
| JP7762311B2 (ja) | 抗成長分化因子１５の抗体分子及びその応用 |